SHR 1681
Alternative Names: SHR-1681Latest Information Update: 06 Feb 2025
Price :
$50 *
At a glance
- Originator Suzhou Suncadia Biopharmaceuticals
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 21 Jan 2025 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (Parenteral) (NCT06737731)
- 31 Dec 2024 Suzhou Suncadia Biopharmaceuticals plans phase-I/II trial for Solid tumours (Late-stage disease, Unresectable/Inoperable, Metastatic disease) in China (Parenteral, Injection) in December 2024 (NCT06737731),
- 23 Dec 2024 Preclinical trials in Solid tumours in China (Parenteral)